Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor and Francis Ltd
Abstract
Iron chelating agents-deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX)-are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis. Each of the approved iron chelating agents has its own advantages over the others and also has its own risks, whether related to over-chelation or not. In this review, we briefly discuss the methods to monitor the efficacy of iron chelation therapy (ICT) and the evidence behind the use of each iron chelating agent. We also portray the risks and complications associated with each iron chelating agent and recommend strategies to manage adverse events. © 2015 Taylor and Francis.
Description
Keywords
Beta-thalassemia, Deferasirox, Deferiprone, Deferoxamine, Iron chelation therapy, Iron overload, Safety, Thalassemia, Benzoates, Chelation therapy, Disease management, Drug-related side effects and adverse reactions, Female, Ferritins, Humans, Iron, Iron chelating agents, Liver, Magnetic resonance imaging, Male, Myocardium, Pregnancy, Pyridones, Triazoles, Ferritin, Iron chelating agent, Benzoic acid derivative, Pyridone derivative, Triazole derivative, Abdominal pain, Agranulocytosis, Arthralgia, Arthropathy, Ataxia, Beta thalassemia, Cataract, Diarrhea, Drug efficacy, Drug safety, Ferritin blood level, Follow up, Gait disorder, Growth retardation, Hearing impairment, Human, Hypertransaminasemia, Iron chelation, Nausea, Nuclear magnetic resonance imaging, Nystagmus, Patient monitoring, Priority journal, Psychomotor disorder, Rash, Review, Skin irritation, Visual disorder, Vomiting, Yersinia infection, Adverse drug reaction, Blood, Cardiac muscle, Complication, Drug effects, Metabolism, Pathology